These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27143429)

  • 1. CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia.
    Enache D; Solomon A; Cavallin L; Kåreholt I; Kramberger MG; Aarsland D; Kivipelto M; Eriksdotter M; Winblad B; Jelic V
    Neurobiol Aging; 2016 Jun; 42():124-31. PubMed ID: 27143429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
    Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased CAIDE dementia risk, cognition, CSF biomarkers, and vascular burden in healthy adults.
    Ecay-Torres M; Estanga A; Tainta M; Izagirre A; Garcia-Sebastian M; Villanua J; Clerigue M; Iriondo A; Urreta I; Arrospide A; Díaz-Mardomingo C; Kivipelto M; Martinez-Lage P
    Neurology; 2018 Jul; 91(3):e217-e226. PubMed ID: 29898969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Midlife CAIDE dementia risk score and dementia-related brain changes up to 30 years later on magnetic resonance imaging.
    Vuorinen M; Spulber G; Damangir S; Niskanen E; Ngandu T; Soininen H; Kivipelto M; Solomon A
    J Alzheimers Dis; 2015; 44(1):93-101. PubMed ID: 25190628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of CAIDE Dementia Risk Score with MRI, PIB-PET measures, and cognition.
    Stephen R; Liu Y; Ngandu T; Rinne JO; Kemppainen N; Parkkola R; Laatikainen T; Paajanen T; Hänninen T; Strandberg T; Antikainen R; Tuomilehto J; Keinänen Kiukaanniemi S; Vanninen R; Helisalmi S; Levälahti E; Kivipelto M; Soininen H; Solomon A
    J Alzheimers Dis; 2017; 59(2):695-705. PubMed ID: 28671114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
    van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
    J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline.
    Bos I; Verhey FR; Ramakers IHGB; Jacobs HIL; Soininen H; Freund-Levi Y; Hampel H; Tsolaki M; Wallin ÅK; van Buchem MA; Oleksik A; Verbeek MM; Olde Rikkert M; van der Flier WM; Scheltens P; Aalten P; Visser PJ; Vos SJB
    Alzheimers Res Ther; 2017 Dec; 9(1):101. PubMed ID: 29284531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medial Temporal Atrophy in Amyloid-Negative Amnestic Type Dementia Is Associated with High Cerebral White Matter Hyperintensity.
    Wong BYX; Yong TT; Lim L; Tan JY; Ng ASL; Ting SKS; Hameed S; Ng KP; Zhou JH; Kandiah N
    J Alzheimers Dis; 2019; 70(1):99-106. PubMed ID: 31177215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment.
    Bouwman FH; Schoonenboom SN; van der Flier WM; van Elk EJ; Kok A; Barkhof F; Blankenstein MA; Scheltens P
    Neurobiol Aging; 2007 Jul; 28(7):1070-4. PubMed ID: 16782233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.
    Kester MI; Goos JD; Teunissen CE; Benedictus MR; Bouwman FH; Wattjes MP; Barkhof F; Scheltens P; van der Flier WM
    JAMA Neurol; 2014 Jul; 71(7):855-62. PubMed ID: 24818585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF biomarkers in frontotemporal lobar degeneration: relations with clinical characteristics, apolipoprotein E genotype, and neuroimaging.
    Pijnenburg YA; Schoonenboom SN; Barkhof F; Knol DL; Mulder C; Van Kamp GJ; Van Swieten JC; Scheltens P
    J Neurol Neurosurg Psychiatry; 2006 Feb; 77(2):246-8. PubMed ID: 16421130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment.
    Selnes P; Aarsland D; Bjørnerud A; Gjerstad L; Wallin A; Hessen E; Reinvang I; Grambaite R; Auning E; Kjærvik VK; Due-Tønnessen P; Stenset V; Fladby T
    J Alzheimers Dis; 2013; 33(3):723-36. PubMed ID: 23186987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment.
    Korf ES; Wahlund LO; Visser PJ; Scheltens P
    Neurology; 2004 Jul; 63(1):94-100. PubMed ID: 15249617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Effects of
    Rosenich E; Bransby L; Yassi N; Fripp J; Laws SM; Martins RN; Fowler C; Rainey-Smith SR; Rowe CC; Masters CL; Maruff P; Lim YY
    Neurology; 2022 Apr; 98(17):e1704-e1715. PubMed ID: 35169009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-sectional and longitudinal associations of motor fluctuations and non-motor predominance with cerebrospinal τ and Aβ as well as dementia-risk in Parkinson's disease.
    Modreanu R; Cerquera SC; Martí MJ; Ríos J; Sánchez-Gómez A; Cámara A; Fernández M; Compta Y
    J Neurol Sci; 2017 Feb; 373():223-229. PubMed ID: 28131192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of progression from mild cognitive impairment to dementia in the placebo-arm of a clinical trial population.
    Prins ND; van der Flier WM; Brashear HR; Knol DL; van de Pol LA; Barkhof F; Scheltens P
    J Alzheimers Dis; 2013; 36(1):79-85. PubMed ID: 23563246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unbiased estimates of cerebrospinal fluid β-amyloid 1-42 cutoffs in a large memory clinic population.
    Bertens D; Tijms BM; Scheltens P; Teunissen CE; Visser PJ
    Alzheimers Res Ther; 2017 Feb; 9(1):8. PubMed ID: 28193256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.